ICU Medical (NASDAQ:ICUI) Price Target Raised to $182.00

ICU Medical (NASDAQ:ICUI) had its target price raised by KeyCorp from $164.00 to $182.00 in a research report released on Tuesday, Marketbeat reports. The firm currently has an overweight rating on the medical instruments supplier’s stock.

Several other equities analysts also recently commented on ICUI. Zacks Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 27th. Piper Sandler lowered their target price on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, BTIG Research assumed coverage on shares of ICU Medical in a report on Monday, June 15th. They issued a “buy” rating and a $170.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, ICU Medical has an average rating of “Buy” and a consensus price target of $172.00.

ICU Medical Price Performance

NASDAQ ICUI opened at $153.46 on Tuesday. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $162.85. The stock’s 50-day moving average is $143.44 and its two-hundred day moving average is $139.62. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The firm has a market cap of $3.83 billion, a P/E ratio of 82.95, a price-to-earnings-growth ratio of 2.20 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The firm’s revenue was down 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, analysts anticipate that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. The trade was a 23.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Revolve Wealth Partners LLC bought a new stake in shares of ICU Medical in the 2nd quarter valued at approximately $243,000. Reinhart Partners LLC. bought a new position in shares of ICU Medical during the 2nd quarter worth approximately $46,148,000. Bank of America Corp DE lifted its position in shares of ICU Medical by 11.2% during the 1st quarter. Bank of America Corp DE now owns 331,739 shares of the medical instruments supplier’s stock worth $42,844,000 after buying an additional 33,508 shares during the period. Edgestream Partners L.P. acquired a new stake in ICU Medical in the 1st quarter valued at $965,000. Finally, Janus Henderson Group PLC boosted its stake in ICU Medical by 3.9% in the 1st quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock valued at $345,607,000 after buying an additional 99,256 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.